News & Updates
Filter by Specialty:

Renal denervation bounces back in 3-year follow-up study
29 Sep 2022
byAudrey Abella
Following negative primary results, the final follow-up of the SYMPLICITY HTN-3 trial takes a turn for the better, demonstrating significant blood pressure (BP) reductions with renal denervation (RDN) in patients with uncontrolled hypertension (HTN).
Renal denervation bounces back in 3-year follow-up study
29 Sep 2022
Telepsychiatry as reliable as face-to-face interviews for symptom assessment
29 Sep 2022
byKanas Chan
Assessments of depressive, anxiety and psychotic symptoms and suicidal risk by telepsychiatry have good reliability in general when compared with face-to-face interviews, according to researchers from the Queen Mary Hospital (QMH).
Telepsychiatry as reliable as face-to-face interviews for symptom assessment
29 Sep 2022
Adjuvant pembrolizumab continues to improve DFS in clear cell RCC
28 Sep 2022
byRoshini Claire Anthony
In patients with clear cell renal cell carcinoma (RCC), adjuvant pembrolizumab continues to improve disease-free survival (DFS) over placebo, according to extended follow-up of the phase III KEYNOTE-564 trial.